Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 11/20 | 0.40 |
| ▸ | EGFR | P00533 | 5/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 3/20 | 0.39 |
| ▸ | HTR1D | P28221 | 3/20 | 0.39 |
| ▸ | HTR1B | P28222 | 3/20 | 0.39 |
| ▸ | HTR7 | P34969 | 2/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | NCF1 | P14598 | 1/20 | 0.35 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2994778 | 1.00 | HTR6 (0.40) | HTR6EGFRITGB3ITGA2BHTR1A | |
| SCHEMBL2993695 | 0.93 | ALDH1A1 (0.46) | EGFRALDH1A1HPGDTSHR | |
| SCHEMBL2990912 | 0.93 | MAPK14 (0.43) | HTR6EGFRHTR1AHTR1DHTR1B | |
| SCHEMBL2990909 | 0.93 | MAPK14 (0.43) | HTR6EGFRHTR1AHTR1DHTR1B | |
| SCHEMBL2993692 | 0.93 | ALDH1A1 (0.46) | EGFRALDH1A1HPGDTSHR | |
| SCHEMBL2988902 | 0.85 | EGFR (0.40) | EGFR | |
| SCHEMBL2988900 | 0.85 | EGFR (0.40) | EGFR | |
| SCHEMBL3639987 | 0.84 | DYRK1A (0.41) | EGFRITGB3ITGA2B | |
| SCHEMBL3639983 | 0.84 | DYRK1A (0.41) | EGFRITGB3ITGA2B | |
| SCHEMBL2993521 | 0.83 | EGFR (0.40) | EGFRALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214455-A1 | Novel Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2008-09-04 | — | — | US | claimed |
| US-20100184774-A1 | METHODS OF TREATMENT | SMITHKLINE BEECHAM CORPORATION | 2010-07-22 | — | — | US | disclosed |
| EP-2164494-A1 | METHODS OF TREATMENT | GlaxoSmithKline LLC (US) | 2010-03-24 | — | — | EP | disclosed |
| WO-2008150837-A1 | METHODS OF TREATMENT | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-11 | — | — | WO | disclosed |
| US-20080214455-A1 | Novel Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214455-A1 | Novel Chemical Compounds | HIPK3, HIPK1, HIPK4 | HTR6 3461/4885EGFR 4159/4885ITGB3 2784/4885 |
| US-20100184774-A1 | METHODS OF TREATMENT | OPRL1, BRCA1, PKD1 | HTR6 53/4885EGFR 2273/4885ITGB3 737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.